Purity Biologics
+70%
Monoclonal Antibody (mAb) Success Rates: At Purity Biologics, we are improving Monoclonal Antibody success rates from an industry average of 45% for phase 3 clinical trials up to 70% through our AI enhanced Purifying Reactor System (PRS) technology which enhances a drug's efficacy and safety.
+2 - 3 Orders of Magnitude
Product Quality: At Purity Biologics, our PRS technology increases a Monoclonal Antibody quality up to 2 and potentially 3 orders-of-magnitude, enhancing efficacy and safety.
+4 to 5 Sigma
Process Quality: At Purity Biologics, using the Six Sigma methodology, our PRS technology increases Monoclonal Antibody's process quality from an industry standard of 3-sigma, up to 4-sigma and potentially 5-sigma, enhancing efficacy and safety.
1-Day vs. 1-Year
Fast AI Analysis & Optimization: At Purity Biologics, our PRS technology can analyze a Monoclonal Antibody Reference Drug and compare it to Drug Master Files in 1-Day vs. the traditional 1-year, enabling a more efficient, optimized, and probable Drug Target Profile development path.
+75%
Cost Savings: At Purity Biologics, our PRS technology can optimize mAb development and manufacturing for up to 75% in cost savings.